Skip to main content

Table 4 Association of rs8061518 with anthropometric, clinical, inflammation and CVD risk biomarkers in children

From: Influence of FTO variants on obesity, inflammation and cardiovascular disease risk biomarkers in Spanish children: a case–control multicentre study

Biomarkers AA AG GG β (95% CI) P P a
N 254 215 54    
Anthropometric factors  
Height (m) 1.39 ± 0.01 1.40 ± 0.01 1.39 ± 0.02 −0.001 (−0.01, 0.00) 0.613 0.107
Weight (kg) 46.8 ± 1.2 44.9 ± 1.3 42.6 ± 2.4 −2.44 (−4.35, -0.54) 0.012 0.130
BMI (kg/m2) 23.70 ± 0.38 22.33 ± 0.42 21.48 ± 0.81 −1.27 (−2.05, -0.50) 0.001 --
BMI z-score 2.16 ± 0.14 1.61 ± 0.14 1.36 ± 0.30 −0.45 (−0.72, -0.17) 0.001 --
Waist circumference (cm) 74.74 ± 1.07 71.99 ± 1.18 71.10 ± 2.25 −1.70 (−4.63, 1.22) 0.254 0.534
Clinical and metabolic biomarkers  
Systolic BP (mm Hg) 106 ± 1 103 ± 1 104 ± 2 −1.74 (−3.69, 0.21) 0.080 0.758
Diastolic BP (mm Hg) 66 ± 1 64 ± 1 61 ± 1 −2.23 (−3.80, -0.65) 0.006 0.083
Glucose (mg/dl) 85 ± 0 84 ± 0 85 ± 1 −0.11 (−1.02, 0.80) 0.816 0.836
Insulin (mU/l) 9.52 ± 0.48 8.56 ± 0.48 8.17 ± 1.13 −0.05 (−0.09, -0.02) 0.003 0.153
HOMA-IR 2.02 ± 0.10 1.80 ± 0.11 1.79 ± 0.30 −0.05 (−0.09, -0.02) 0.003 0.153
Triacylglycerols (mg/dl) 68 ± 2 63 ± 2 66 ± 6 −2.33 (−6.52, 1.86) 0.276 0.995
ApoAI (mg/dl) 141 ± 2 137 ± 2 145 ± 4 0.15 (−3.40, 3.71) 0.932 0.330
Cholesterol (mg/dl) 166 ± 2 168 ± 2 172 ± 4 0.01 (−0.004, 0.02) 0.223 0.287
HDL-c (mg/dl) 57 ± 1 56 ± 1 58 ± 2 0.07 (−1.87, 2.01) 0.945 0.107
Adiponectin (mg/l) 25.46 ± 0.77 23.92 ± 0.73 27.90 ± 1.81 0.38 (−1.15, 1.91) 0.628 0.741
Resistin (μg/l) 11.34 ± 0.40 10.30 ± 0.33 10.37 ± 0.72 −0.68 (−1.42, 0.06) 0.074 0.227
Leptin (μg/l) 16.98 ± 1.02 12.57 ± 0.85 11.21 ± 1.70 −3.55 (−5.43, -1.66) <0.001 0.041
Inflammatory biomarkers  
C-reactive protein (mg/l) 2.50 ± 0.26 2.26 ± 0.31 1.70 ± 0.30 −0.34 (−0.89, 0.20) 0.217 0.784
IL-6 (ng/l) 5.62 ± 0.64 6.56 ± 0.90 4.71 ± 0.91 0.09 (−1.36, 1.53) 0.905 0.705
IL-8 (ng/l) 1.94 ± 0.14 1.98 ± 0.17 1.57 ± 0.19 −0.10 (−0.39, 0.19) 0.495 0.804
TNFα (ng/l) 3.62 ± 0.14 3.51 ± 0.14 3.60 ± 0.27 −0.05 (−0.32, 0.22) 0.711 0.696
Cardiovascular disease risk biomarkers  
MMP-9 (μg/l) 82.62 ± 3.42 86.21 ± 4.14 84.12 ±8.05 0.01 (−0.03, 0.04) 0.764 0.754
MPO (μg/l) 19.19 ± 1.68 16.65 ± 1.44 16.55 ± 4.26 −1.63 (−4.94, 1.68) 0.336 0.712
sE-Selectin (μg/l) 28.19 ± 0.98 26.13 ± 1.08 26.61 ± 2.34 −1.09 (−3.13, 0.95) 0.296 0.924
sICAM-1 (mg/l) 0.165 ± 0.004 0.168 ± 0.005 0.155 ± 0.007 −0.002 (−0.01, 0.01) 0.605 0.923
Active PAI-1 (μg/l) 9.81 ± 0.62 8.45 ± 0.49 6.16 ± 0.63 −1.71 (−2.80, -0.62) 0.002 0.067
Total PAI-1 (μg/l) 24.74 ± 1.11 22.56 ± 1.16 20.66 ± 1.85 −0.04 (−0.08, 0.003) 0.073 0.350
  1. CI: Confidence Interval; BMI: body mass index; BP: blood pressure; HOMA-IR: homeostasis model assessment for insulin resistance; HDL-c: High-density lipoprotein-cholesterol; IL: interleukin; TNFα: tumour necrosis factor alpha; MMP-9: matrix metalloproteinase-9; MPO: myeloperoxidase; sICAM-1: soluble intracellular adhesion molecule-1; PAI-1: plasminogen activator inhibitor-1. β coefficients represent the change in absolute traits values of each additional risk allele. General linear models were used to examine associations, P adjusted by age and sex, Pa adjusted by age, sex, and BMI.
\